{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:09:11Z","timestamp":1788314951970,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T00:00:00Z","timestamp":1588982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["13312"],"award-info":[{"award-number":["13312"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics: X"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ijpx.2020.100049","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T19:35:41Z","timestamp":1589657741000},"page":"100049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model"],"prefix":"10.1016","volume":"2","author":[{"given":"Aida","family":"Varela-Moreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demian","family":"van Straten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen F.","family":"van Leur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruud W.J.","family":"Ruiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Deshantri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim E.","family":"Hennink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel H.A.M.","family":"Fens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.J.","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1012-9815","authenticated-orcid":false,"given":"Raymond M.","family":"Schiffelers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpx.2020.100049_bb0005","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: A suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ijpx.2020.100049_bb0010","series-title":"Kyprolis\u2122 (carfilzomib) for injection","author":"FDA, U. S. F. A. D. A","year":"2012"},{"key":"10.1016\/j.ijpx.2020.100049_bb0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jconrel.2017.07.013","article-title":"A systematic comparison of clinically viable nanomedicines targeting hmg-coa reductase in inflammatory atherosclerosis","volume":"262","author":"Alaarg","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2020.100049_bb0020","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1517\/14712598.2014.953050","article-title":"Carfilzomib in multiple myeloma","volume":"14","author":"Andreu-Vieyra","year":"2014","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ijpx.2020.100049_bb0025","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/jpet.115.226993","article-title":"Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines","volume":"355","author":"Ao","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijpx.2020.100049_bb0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jbspin.2009.10.009","article-title":"New treatments for myeloma","volume":"77","author":"Aza\u00efs","year":"2010","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.ijpx.2020.100049_bb0035","doi-asserted-by":"crossref","first-page":"15495","DOI":"10.1021\/acs.langmuir.8b03576","article-title":"Effect of formulation and processing parameters on the size of mpeg-b-p(hpma-bz) polymeric micelles","volume":"34","author":"Bagheri","year":"2018","journal-title":"Langmuir."},{"key":"10.1016\/j.ijpx.2020.100049_bb0040","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nnano.2011.166","article-title":"Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size","volume":"6","author":"Cabral","year":"2011","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ijpx.2020.100049_bb0045","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1093\/ndt\/gfs449","article-title":"Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities","volume":"27","author":"Davenport","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ijpx.2020.100049_bb0050","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jconrel.2018.08.034","article-title":"Nanomedicines for the treatment of hematological malignancies","volume":"287","author":"Deshantri","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2020.100049_bb0055","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jconrel.2019.01.028","article-title":"Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma","volume":"296","author":"Deshantri","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2020.100049_bb0060","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jconrel.2013.09.013","article-title":"Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles","volume":"172","author":"Ernsting","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2020.100049_bb0065","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jconrel.2012.06.029","article-title":"Hpma copolymer-doxorubicin conjugates: the effects of molecular weight and architecture on biodistribution and in vivo activity","volume":"164","author":"Etrych","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2020.100049_bb0070","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ijpx.2020.100049_bb0075","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1182\/blood-2012-03-414920","article-title":"Reconstructing the human hematopoietic niche in immunodeficient mice: Opportunities for studying primary multiple myeloma","volume":"120","author":"Groen","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.ijpx.2020.100049_bb0080","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.actbio.2018.09.022","article-title":"Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma","volume":"80","author":"Gu","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ijpx.2020.100049_bb0085","first-page":"87","article-title":"Incidence and management of adverse events in patients with relapsed and\/or refractory multiple myeloma receiving single-agent carfilzomib","volume":"6","author":"Harvey","year":"2014","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.ijpx.2020.100049_bb0090","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"U.S. Food and drug administration approval: Carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijpx.2020.100049_bb0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1517\/17425240903380446","article-title":"Overcoming the barriers in micellar drug delivery: Loading efficiency, in vivo stability, and micelle-cell interaction","volume":"7","author":"Kim","year":"2010","journal-title":"Expert Opin Drug Deliv."},{"key":"10.1016\/j.ijpx.2020.100049_bb0100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with imids and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia."},{"key":"10.1016\/j.ijpx.2020.100049_bb0105","doi-asserted-by":"crossref","first-page":"157496","DOI":"10.1155\/2012\/157496","article-title":"Bone marrow microenvironment in multiple myeloma progression","volume":"2012","author":"Manier","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.ijpx.2020.100049_bb0110","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1089\/107999099313983","article-title":"A novel immunodeficient mouse model--rag2 x common cytokine receptor gamma chain double mutants--requiring exogenous cytokine administration for human hematopoietic stem cell engraftment","volume":"19","author":"Mazurier","year":"1999","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.ijpx.2020.100049_bb0115","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ejpb.2015.06.010","article-title":"Hpma-based polymeric micelles for curcumin solubilization and inhibition of cancer cell growth","volume":"94","author":"Naksuriya","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpx.2020.100049_bb0120","first-page":"13","article-title":"Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib","volume":"7","author":"Nooka","year":"2013","journal-title":"Biologics."},{"key":"10.1016\/j.ijpx.2020.100049_bb0125","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/jjco\/hyy108","article-title":"Proteasome inhibitors for multiple myeloma","volume":"48","author":"Okazuka","year":"2018","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.ijpx.2020.100049_bb0130","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpx.2020.100049_bb0135","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-013-2267-x","article-title":"A phase i\/ii study of carfilzomib 2\u201310-min infusion in patients with advanced solid tumors","volume":"72","author":"Papadopoulos","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ijpx.2020.100049_bb0140","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1200\/JCO.2013.52.3522","article-title":"Phase i study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and\/or refractory multiple myeloma","volume":"33","author":"Papadopoulos","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijpx.2020.100049_bb0145","article-title":"Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice","volume":"12","author":"Park","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpx.2020.100049_bb0150","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1089\/ten.tea.2008.0666","article-title":"Bone-forming capacity of mesenchymal stromal cells when cultured in the presence of human platelet lysate as substitute for fetal bovine serum","volume":"15","author":"Prins","year":"2009","journal-title":"Tissue Eng. A"},{"key":"10.1016\/j.ijpx.2020.100049_bb0155","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.2174\/1381612821666150304161201","article-title":"Understanding the interaction between human serum albumin and anti-bacterial\/ anti-cancer compounds","volume":"21","author":"Rehman","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ijpx.2020.100049_bb0160","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ijpx.2020.100049_bb0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1259\/bjr\/31542964","article-title":"Spleen in haematological malignancies: Spectrum of imaging findings","volume":"85","author":"Saboo","year":"2012","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.ijpx.2020.100049_bb0170","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jpba.2016.03.015","article-title":"A uhplc-uv-qtof study on the stability of carfilzomib, a novel proteasome inhibitor","volume":"124","author":"Sestak","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ijpx.2020.100049_bb0175","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1021\/acsnano.5b00929","article-title":"Complete regression of xenograft tumors upon targeted delivery of paclitaxel via pi-pi stacking stabilized polymeric micelles","volume":"9","author":"Shi","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.ijpx.2020.100049_bb0180","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1021\/acs.biomac.7b00068","article-title":"Enhancing tumor penetration of nanomedicines","volume":"18","author":"Sun","year":"2017","journal-title":"Biomacromolecules."},{"key":"10.1016\/j.ijpx.2020.100049_bb0185","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1021\/ar2003336","article-title":"Metabolism of nanomaterials in vivo: Blood circulation and organ clearance","volume":"46","author":"Wang","year":"2013","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ijpx.2020.100049_bb0190","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/dmd.112.047662","article-title":"Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib","volume":"41","author":"Wang","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpx.2020.100049_bb0195","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1124\/dmd.111.039164","article-title":"Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats","volume":"39","author":"Yang","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpx.2020.100049_bb0200","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1023\/A:1021191432366","article-title":"A comparison of the osteoinductive potential of two calcium phosphate ceramics implanted intramuscularly in goats","volume":"13","author":"Yuan","year":"2002","journal-title":"J. Mater. Sci. Mater. Med."}],"container-title":["International Journal of Pharmaceutics: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156720300116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156720300116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T06:02:01Z","timestamp":1778911321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590156720300116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":40,"alternative-id":["S2590156720300116"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpx.2020.100049","relation":{},"ISSN":["2590-1567"],"issn-type":[{"value":"2590-1567","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpx.2020.100049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100049"}}